Sera Prognostics (SERA) Corporate presentation summary

Market need and healthcare impact

• Preterm birth rates in the US have risen from 9.4% to 10.4% between 2013 and 2024, with NICU admissions increasing from 8.7% to 9.8% between 2016 and 2023.

• Preterm births account for 61% of neonatal costs, with extremely premature births costing up to $344,355 per delivery and 7x higher healthcare costs over seven years.

• Traditional screening methods miss 81% of women who will experience preterm birth, and only 20% of mothers receive information on preterm labor risk at their first prenatal appointment.

Product innovation and scientific foundation

• The PreTRM test is a proteomics-based, blood biomarker test that predicts spontaneous preterm birth risk before symptoms arise.

• Key biomarkers IGFBP4 and SHBG, discovered in partnership with 13 institutions, are used to assess risk.

• The test integrates seamlessly into prenatal care, with results delivered in five days from a CLIA-certified lab.

Clinical validation and outcomes

• PreTRM is the only clinically validated test for early prediction of premature birth, supported by 11+ published studies and a biobank of 20,000 samples.

• The PRIME randomized controlled trial (n=5,018) showed 20% fewer NICU admissions, 56% fewer births before 32 weeks, and a 20% reduction in neonatal morbidity odds.

• Each day of gestational age gained among the earliest 10% of births was prolonged by 4.5 days on average.